Epilepsy – Unmet Need – Unmet Need – Epilepsy: Lennox-Gastaut Syndrome (US/EU)
Lennox-Gastaut syndrome (LGS) is a severe pediatric-onset epilepsy syndrome characterized by developmental delay or regression, multiple seizure types, and electroencephalographic abnormalities. Tonic and atonic seizures are the most prevalent seizure forms associated with LGS. A limited number of antiepileptic drugs (AEDs) are approved for adjunctive treatment of LGS, namely, Fintepla (fenfluramine), Epidiolex (cannabidiol), rufinamide, lamotrigine, and clobazam. However, significant unmet need in the treatment of LGS remains because most patients do not achieve complete seizure control with currently available AEDs. This report provides insights on the most important factors influencing prescribers’ clinical decisions and driving their perceptions of current therapies. These insights will guide drug developers on the optimal positioning and differentiation of new products for the treatment of this rare form of epilepsy.
Questions answered
- What are the treatment drivers and goals in LGS?
- What attributes drive decision-making in LGS, which have limited impact, and which are hidden opportunities?
- How do key agents (e.g., Epidiolex, Fintepla, rufinamide) perform on clinical attributes?
- What are the prevailing areas of unmet need and opportunity in LGS?
- Based on a conjoint analysis and TPP simulation, what trade-offs across different clinical attributes and prices are acceptable to neurologists for a hypothetical new LGS drug?
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European neurologists fielded in February 2024
Key companies: Jazz Pharmaceuticals, UCB Pharmaceuticals
Key drugs: Epidiolex / Epidyolex, Fintepla, clobazam, lamotrigine, rufinamide, topiramate, valproic acid / valproate
Product description
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.
Key feature
The Target Product Profile (TPP) Simulator tool allows for customizable market simulations based on conjoint analysis that depicts how physicians make decisions based on actual behavior rather than opinion. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.
